Key result
Extended DAPT linked to ~55% fewer major cardiac events in East Asians with high DAPT scores.
Why the study?
It was uncertain whether the DAPT score could adequately risk stratify patients receiving exclusively second-generation DES, particularly in an East Asian population.
Does the DAPT score adequately risk stratify East Asian patients receiving exclusively second-generation DES to predict clinical outcomes and benefit from extended DAPT?
Cohort (n=8,383)
Does the DAPT score adequately risk stratify East Asian patients receiving exclusively second-generation DES to predict clinical outcomes and benefit from extended DAPT?
Effect estimate: HR 0.45 (95% CI 0.27-0.76)
Absolute Event Rate: 1.8% vs 3.7%
p-value: p=.003
The DAPT score is an effective risk stratification tool for East Asian patients with second-generation DES, identifying those who benefit from extended DAPT without a significant increase in bleeding risk.
Supports DAPT score stratification for extended therapy decisions in East Asians with second-generation DES; extends validation but leaves open need for randomized confirmation.
OBJECTIVES: We investigated whether the dual antiplatelet therapy (DAPT) score (DS) predicts clinical outcome in an East-Asian population that received exclusively second generation drug-eluting stent (DES). BACKGROUNDS: It is uncertain whether the DS could adequately risk stratify patients exclusively receiving second generation DES. METHODS: From the Grand-DES registry, we evaluated patients who were treated with DAPT for at least 12 months and were event-free at 12 months after DES implantation. Patients were classified into two categories: high DS (≧2) (n = 3,157); and low DS (<2) (n = 5,226). The primary ischemic outcome was a composite of stent thrombosis and all myocardial infarction (MI), and the primary bleeding outcome was TIMI major or minor bleeding. A propensity score (PS)-matched analysis was done to correct for baseline differences between extended DAPT group and the conventional group. RESULTS: Among 8,383 subjects, the primary ischemic outcome occurred in 48 patients (0.6%) and the primary bleeding outcome in 49 patients (0.6%). High DS was associated with a higher incidence of ischemic events (ischemic outcome: 0.8% vs. 0.4%, for high vs. low DS, Log-rank p = .039), but not with any differences in bleeding events (Log-rank p = .734). In the PS-matched analysis, extended group was associated with lower risk of composite endpoint of MI, stent thrombosis, or cardiac death in only the high DS group (1.8% vs. 3.7%, Log-rank p = .004; hazard ratio 0.45, 95% confidence interval 0.27-0.76; p = .003 after adjustment). CONCLUSIONS: The DS was an adequate risk stratifier for future ischemic events in East Asians receiving exclusively second generation DES.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) conducted a cohort in Percutaneous coronary intervention with second generation drug-eluting stents (n=8,383). Extended DAPT vs. Conventional DAPT was evaluated on Composite of MI, stent thrombosis, or cardiac death in high DAPT score group (HR 0.45, 95% CI 0.27-0.76, p=.003). In East Asian patients receiving second-generation DES, extended DAPT reduced the risk of MI, stent thrombosis, or cardiac death in those with a high DAPT score (HR 0.45; 95% CI 0.27-0.76; p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: